Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SARC-GYN1: Adjuvant Polychemotherapy + Radiotherapy in Uterine Sarcoma
NCT00162721Phase 3Unknown
- Sponsor
- Gustave Roussy
- Start
- Sep 2001
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of doxorubicin, ifosfamide and cisplatin in uterine sarcoma (2 arms), sponsored by Gustave Roussy. Primary endpoint: Event-Free Survival at 3 years. Status: unknown.
02
Drugs
doxorubicinifosfamidecisplatin
03
Conditions
uterine sarcoma
Beyond the preview
Go deeper on NCT00162721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00162721.